Iacoboni, Gloria http://orcid.org/0000-0003-0805-9288
Simó, Marc
Villacampa, Guillermo
Catalá, Eva
Carpio, Cecilia
Díaz-Lagares, Cándido
Vidal-Jordana, Ángela
Bobillo, Sabela
Marín-Niebla, Ana
Pérez, Ana
Jiménez, Moraima
Abrisqueta, Pau
Bosch, Francesc
Barba, Pere
Article History
Received: 18 December 2020
Accepted: 18 May 2021
First Online: 8 July 2021
Declarations
:
: All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008.
: Informed consent was obtained from all patients for being included in the study.
: G.I. declares having received honoraria from Celgene, Gilead, Novartis, and Roche, not related with the present article. G.V. reported receiving honoraria for speaker activities from Merck Sharp & Dohme and advisory role from Astrazeneca. E.C. declares having no conflict of interest. C.C. declares having received honoraria from Takeda and Regeneron, not related with the present article. C. D-L declares having received honoraria from Celgene and Novartis, not related with the present article. A.V.J. received funding from Fondo de Investigaciones Sanitarias and Instituto de Salud Carlos III (FIS PI17/02162); and has engaged in consulting and/or participated as speaker in events organized by Novartis, Roche, Teva, Mylan, Biogen, Merck, and Sanofi. A.P. declares having no conflict of interest. M.J. declares having no conflict of interest. P.A. declares having received honoraria from Celgene, Gilead, Janssen, Abbvie, and Roche, not related with the present article. F.B. declares having received honoraria from Celgene, Gilead, Novartis, Pfizer, and Roche, not related with the present article. P.B. declares having received honoraria from Amgen, Celgene, Gilead, Incyte, Jazz Pharmaceuticals, MSD, Novartis, Pfizer, and Roche, not related with the present article. P.B. received funding from the Carlos III FIS16/01433 Health Institute, Asociación Española contra el Cáncer (Ideas Semilla 2019) and a PERIS 2018–2020 grant from the Generalitat de Catalunya (BDNS357800).